All In Biotech

Drug Trial Radar · NCT02688933

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 638 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

638

Actual

Start

May 5, 2016

Primary completion

Jun 19, 2017

Study completion Jun 19, 2017

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Feb 23, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To demonstrate that morning injection of Toujeo (HOE901-U300) compared to Lantus provides better glycemic control evaluated by Continuous Glucose Monitoring (CGM) in adult participants with type 1 diabetes mellitus. Secondary Objective: To demonstrate that treatment with HOE901-U300 compared to Lantus provides: * Lower incidence rate of nocturnal symptomatic hypoglycemia; * Better glucose control coverage during the last hours of CGM before next basal-insulin dosing; * Less variability in CGM profile.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

  • HOE901-U300 (Insulin Glargine 300 U/ml)Drug

    Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast) using a pre-filled pen.

  • Lantus (Insulin Glargine 100 U/ml)Drug

    Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast using a pre-filled pen.

  • Mandated back ground therapyDrug

    Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening. Mealtime insulin was to be continued during the study and titrated towards protocol specified postprandial glucose targets (130-180 mg/dL).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Time of Mean Glucose Concentration Within the Target Range of 70-180 mg/dL as Obtained From CGMTime frame: During Week 15 and/or 16

Locations

100 sites in 2 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840-151

    Little Rock, Arkansas

  • Investigational Site Number 840-071

    Concord, California

  • Investigational Site Number 840-149

    Escondido, California

  • Investigational Site Number 840-004

    Fresno, California

  • Investigational Site Number 840-110

    Greenbrae, California

  • Investigational Site Number 840-124

    La Jolla, California

  • Investigational Site Number 840-030

    La Mesa, California

  • Investigational Site Number 840-044

    Los Angeles, California

  • Investigational Site Number 840-022

    Los Angeles, California

  • Investigational Site Number 840-129

    Los Gatos, California

  • Investigational Site Number 840-024

    Northridge, California

  • Investigational Site Number 840-069

    Pomona, California

  • Investigational Site Number 840-090

    Pomona, California

  • Investigational Site Number 840-132

    Rolling Hills Estates, California

  • Investigational Site Number 840-130

    San Jose, California

  • Investigational Site Number 840-055

    San Ramon, California

  • Investigational Site Number 840-028

    Santa Barbara, California

  • Investigational Site Number 840-063

    Tarzana, California

  • Investigational Site Number 840-138

    Tustin, California

  • Investigational Site Number 840-016

    Ventura, California

  • Investigational Site Number 840-039

    Denver, Colorado

  • Investigational Site Number 840-021

    Denver, Colorado

  • Investigational Site Number 840-070

    Denver, Colorado

  • Investigational Site Number 840-046

    Englewood, Colorado

  • Investigational Site Number 840-072

    Coral Gables, Florida

  • Investigational Site Number 840-133

    Hialeah, Florida

  • Investigational Site Number 840-137

    Maitland, Florida

  • Investigational Site Number 840-049

    Miami, Florida

  • Investigational Site Number 840-076

    Miami, Florida

  • Investigational Site Number 840-023

    New Port Richey, Florida

  • Investigational Site Number 840-053

    Ocoee, Florida

  • Investigational Site Number 840-112

    Ormond Beach, Florida

  • Investigational Site Number 840-018

    Palm Harbor, Florida

  • Investigational Site Number 840-047

    Port Charlotte, Florida

  • Investigational Site Number 840-114

    Tampa, Florida

  • Investigational Site Number 840-036

    West Palm Beach, Florida

  • Investigational Site Number 840-001

    Atlanta, Georgia

  • Investigational Site Number 840-064

    Columbus, Georgia

  • Investigational Site Number 840-012

    Lawrenceville, Georgia

  • Investigational Site Number 840-008

    Roswell, Georgia

Showing 40 of 100 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.